CLINICAL TRIALS PROFILE FOR OCALIVA

All Clinical Trials for ocaliva

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04939051 ↗	Obeticholic Acid for Prevention in Barrett's Esophagus	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2021-12-08	This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid, may help increase bile flow from the liver while suppressing bile acid production, therefore reducing the exposure of the liver to toxic levels of bile acids which is potentially linked to cancer development.
NCT05112822 ↗	Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)	Not yet recruiting	M.D. Anderson Cancer Center	Phase 1	2022-03-31	This is a trial that intends to evaluate the effect of treatment with the drug obeticholic acid in the treatment of the Familial Adenomatous Polyposis condition.
NCT05223036 ↗	Testing Obeticholic Acid for Familial Adenomatous Polyposis	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2022-07-11	This phase IIa trial investigates if giving obeticholic acid (OCA) has an effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to bile acids, a fluid made and released by the liver. It binds to a receptor in the intestine that is believed to have a positive effect on preventing cancer development. OCA has been effective in treating primary biliary cholangitis (PBC), a liver disease, and is approved by the Food and Drug Administration (FDA). There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.
NCT05740631 ↗	The Effect of Obeticholic Acid in Healthy Volunteers	Recruiting	Intercept Pharmaceuticals	N/A	2022-08-22	This study investigates whether obeticholic acid affects gut microbiota, gastric motility, accommodation, and gastrointestinal peptide in healthy subjects. This study is a single-blind, placebo-controlled, randomized study. Twelve healthy volunteers will take one tablet containing obeticholic acid (10 mg) or a placebo once per day for 21 days for the first intervention. After 28 days washout period, they will take a tablet different from the one taken in the first intervention. Before the first intervention, they will receive MMC, IGP and endoscopy exam. At the end of the first and second interventions, they will receive the same exams. During MMC&IGP, we will take blood samples to measure plasma hormones (motilin, octa-ghrelin, GLP-1, GLP-2, GIP, and insulin) and take duodenal fluid. When the endoscopy, we will take samples from the duodenal for microbiota, permeability measurement, RNA, protein, and pathology. Before and during the interventions, stool samples will be collected.
NCT05740631 ↗	The Effect of Obeticholic Acid in Healthy Volunteers	Recruiting	Universitaire Ziekenhuizen KU Leuven	N/A	2022-08-22	This study investigates whether obeticholic acid affects gut microbiota, gastric motility, accommodation, and gastrointestinal peptide in healthy subjects. This study is a single-blind, placebo-controlled, randomized study. Twelve healthy volunteers will take one tablet containing obeticholic acid (10 mg) or a placebo once per day for 21 days for the first intervention. After 28 days washout period, they will take a tablet different from the one taken in the first intervention. Before the first intervention, they will receive MMC, IGP and endoscopy exam. At the end of the first and second interventions, they will receive the same exams. During MMC&IGP, we will take blood samples to measure plasma hormones (motilin, octa-ghrelin, GLP-1, GLP-2, GIP, and insulin) and take duodenal fluid. When the endoscopy, we will take samples from the duodenal for microbiota, permeability measurement, RNA, protein, and pathology. Before and during the interventions, stool samples will be collected.

Clinical Trial Conditions for ocaliva

Condition Name

Condition Name for ocaliva
Intervention	Trials
Familial Adenomatous Polyposis	2
Healthy	1
Attenuated Familial Adenomatous Polyposis	1
Barrett Esophagus	1

Condition MeSH

Condition MeSH for ocaliva
Intervention	Trials
Adenomatous Polyposis Coli	2
Nasopharyngeal Neoplasms	2
Colorectal Neoplasms	2
Barrett Esophagus	1

Clinical Trial Locations for ocaliva

Trials by Country

Trials by Country for ocaliva
Location	Trials
United States	5
Belgium	1
Puerto Rico	1

Trials by US State

Trials by US State for ocaliva
Location	Trials
Texas	1
Ohio	1
Michigan	1
Massachusetts	1
Arizona	1

Clinical Trial Progress for ocaliva

Clinical Trial Phase

Clinical Trial Phase for ocaliva
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for ocaliva
Clinical Trial Phase	Trials
Not yet recruiting	3
Recruiting	1

Clinical Trial Sponsors for ocaliva

Sponsor Name

Sponsor Name for ocaliva
Sponsor	Trials
National Cancer Institute (NCI)	2
M.D. Anderson Cancer Center	1
Intercept Pharmaceuticals	1

Sponsor Type

Sponsor Type for ocaliva
Sponsor	Trials
NIH	2
Other	2
Industry	1

Ocaliva Market Analysis and Financial Projection

OCALIVA: Clinical Trials, Market Analysis, and Projections

Introduction to OCALIVA

OCALIVA, also known as obeticholic acid, is a farnesoid X receptor agonist developed by Intercept Pharmaceuticals for the treatment of primary biliary cholangitis (PBC), a chronic liver disease. Here, we will delve into the current status of its clinical trials, market analysis, and future projections.

Clinical Trials Update

Accelerated Approval and Postmarket Trials

OCALIVA received accelerated approval from the FDA in 2016 for the treatment of PBC. However, as part of the accelerated approval process, the FDA required additional postmarket clinical trials to verify the clinical benefit of the drug[4][5].

Trial 747-302: Efficacy and Safety Concerns

One of the key trials, 747-302, was designed to evaluate the efficacy of OCALIVA in preventing liver transplantation, death, and other liver-related outcomes in PBC patients. However, the trial failed to demonstrate efficacy on its primary composite endpoint. The FDA analysis showed unfavorable trends in liver transplantation and mortality among patients treated with OCALIVA compared to those receiving placebo[5].

External Control Group Analysis

Despite the challenges in the 747-302 trial, an external control group analysis derived from the Komodo Health US claims database showed that OCALIVA treatment resulted in a statistically significant and clinically meaningful reduction in death, liver transplant, and hepatic decompensation compared to the non-OCA-treated external control group[1].

Trial 747-401: Pharmacokinetic and Pharmacodynamic Profiles

Another postmarket confirmatory trial, 747-401, aimed to evaluate the pharmacokinetic and pharmacodynamic profiles of OCALIVA in PBC patients with Child-Pugh classes B and C. However, this trial was terminated due to reports of hepatotoxicity associated with OCALIVA, leading to substantial changes in the drug’s boxed warning and safety labels[5].

Market Analysis

Global Market Forecast

The global market for OCALIVA is subject to various factors, including regulatory milestones, competitive landscape, and emerging therapies. The market is expected to evolve significantly due to extensive research and incremental healthcare spending worldwide. From 2024 to 2032, the market size for OCALIVA in PBC is forecasted to change based on these dynamics[3].

Competitive Landscape

The PBC market is becoming increasingly competitive with the development of novel therapies. Other emerging products for PBC are expected to provide tough competition to OCALIVA. The launch of late-stage emerging therapies in the near future will significantly impact the market, potentially altering OCALIVA’s dominance[3].

Regional Analysis

The market assessment of OCALIVA covers major regions including the United States, Germany, France, Italy, Spain, and the United Kingdom. This regional analysis provides insights into the forecasted sales data and market trends specific to each region[3].

Regulatory Milestones and Development Activities

Current Regulatory Status

The FDA has been assessing the safety data of OCALIVA and has not approved the supplemental New Drug Application (sNDA) in its current form. Intercept Pharmaceuticals remains committed to working closely with the FDA to address the concerns and ensure the drug’s continued availability for patients with limited treatment options[1].

Developmental Activities

The report highlights the regulatory milestones and developmental activities of OCALIVA, including clinical trials information, trial interventions, and trial status. These activities are crucial for understanding the current development scenario of OCALIVA in PBC[3].

Safety and Efficacy Concerns

Liver Safety and Hepatotoxicity

The FDA has flagged serious liver injury and hepatotoxicity associated with OCALIVA, leading to changes in the drug’s safety labels. The postmarket clinical trial data showed higher risks of liver transplant and death among patients receiving OCALIVA compared to those receiving placebo[4][5].

Patient Impact

The safety concerns have significant implications for patients. For instance, in the 747-302 trial, 7 out of 81 patients receiving OCALIVA required a liver transplant, compared to 1 out of 68 patients in the placebo group. Additionally, four patients receiving OCALIVA died, compared to one in the placebo group[4].

Market Projections

Forecasted Sales Data

The forecasted sales data for OCALIVA from 2024 to 2032 will be influenced by the regulatory outcomes, competitive landscape, and the launch of emerging therapies. The market analysis provides a detailed overview of the expected sales trends and market size during this period[3].

SWOT Analysis

A comprehensive SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) is included in the market report, providing analyst views on OCALIVA’s position in the PBC market. This analysis helps in understanding the overall market attractiveness and potential challenges[3].

Consumer Behavior and Market Trends

Consumer Behavior Analysis

The market report includes an analysis of consumer behavior, which is crucial for understanding the demand and acceptance of OCALIVA among patients and healthcare providers. This analysis helps in identifying market trends and opportunities[2].

Technological and ESG Trends

The report also covers technological trends, ESG (Environmental, Social, and Governance) analysis, and other market drivers and restraints. These factors are essential for a holistic understanding of the market dynamics and future projections[2].

Key Takeaways

• OCALIVA's accelerated approval for PBC is under scrutiny due to concerns over its efficacy and safety.
• Clinical trials, including 747-302 and 747-401, have raised significant issues regarding liver safety and hepatotoxicity.
• The global market for OCALIVA is forecasted to be impacted by emerging therapies and regulatory milestones.
• The competitive landscape in the PBC market is becoming increasingly complex with new treatments on the horizon.
• Intercept Pharmaceuticals is working closely with the FDA to address the concerns and ensure the drug’s continued availability.

FAQs

What is OCALIVA used for?

OCALIVA (obeticholic acid) is used for the treatment of primary biliary cholangitis (PBC), a chronic liver disease.

Why is OCALIVA's approval under scrutiny?

OCALIVA's approval is under scrutiny due to concerns over its efficacy and safety, particularly regarding liver safety and hepatotoxicity, as highlighted in postmarket clinical trials.

What are the key findings from the 747-302 trial?

The 747-302 trial failed to demonstrate efficacy on its primary composite endpoint of liver transplantation, death, and other liver-related outcomes. It also showed unfavorable trends in liver transplantation and mortality among patients treated with OCALIVA.

How will emerging therapies impact the market for OCALIVA?

Emerging therapies for PBC are expected to provide tough competition to OCALIVA, potentially altering its market dominance. The launch of late-stage emerging therapies will significantly impact the market size and trends.

What are the regulatory next steps for OCALIVA?

Intercept Pharmaceuticals is working closely with the FDA to address the concerns raised by the postmarket clinical trials. The FDA will continue to assess the safety data and may require additional studies or changes to the drug’s labeling.

Cited Sources:

1. FDA Denies Full Approval of Obeticholic Acid for Primary Biliary Cholangitis - EMPR News
2. Global Ocaliva Market Report 2024 Edition - Cognitive Market Research
3. OCALIVA for Primary Biliary Cirrhosis (PBC) Drug Landscape Report 2024 - GlobeNewswire
4. Serious Liver Injury Being Observed in Patients without Cirrhosis | FDA - FDA
5. Intercept's Ocaliva in Jeopardy as FDA Questions Efficacy, Safety - BioSpace